





PAP therapy just for you. **Say hello to next-level sleep**.

Start dreaming again.

One of the most inspiring things people tell us about using positive airway pressure (PAP) therapy is that they dream again. Welcome to the ResMed AirCurve 11 ASV*, the bilevel PAP device for people like you with central sleep apnea (CSA), obstructive sleep apnea (OSA) or a combination of sleep disordered breathing.

About central sleep apnea (CSA)

CSA occurs when a person's central control of breathing is impaired. CSA can emerge after a person has been exposed to PAP treatment. This is referred to as treatment emergent central sleep apnea (TECSA) or as complex sleep apnea (CompSA). The overall prevalence of CSA in patients taking chronic opioids is 24%¹. CSA may be caused by underlying medical conditions such as heart failure and stroke. CSA can even result from sleeping at higher altitude.²,3

A few signs and symptoms of CSA include observed episodes of interruption of breathing during sleep, morning headaches and difficulty concentrating. People with CSA tend to hyperventilate and present with unstable breathing while sleeping.⁵

Breathe easy

With a goal to stabilize breathing, ASV* stands for "adaptive servo-ventilation." Your AirCurve 11 ASV device detects your breathing pattern and adapts to deliver personalized therapy while you sleep in sync with your natural breath cycle.





Built-in support from the beginning



Using PAP therapy does not have to feel overwhelming. Your AirCurve 11 ASV* offers multiple support tools to help you feel comfortable early in your PAP therapy journey, including myAir™, Care Check-In, Personal Therapy Assistant and Test Drive. These digital health solutions are designed to help you start and benefit from therapy from the moment you get your AirCurve 11.


myAir

myAir is an online coaching and support program and app to help you begin PAP therapy." It lets you track your sleep and therapy progress with a daily sleep score and encourages you—it's like having your own personal sleep coach." Easy-to-follow prompts in myAir help you get it set up to then access the helpful videos, tips, messaging, and even cleaning support for your device, mask and more.

Care Check-In

Care Check-In is available on your device or on myAir after successful device pairing. Care Check-In will start by asking you a few questions, unique to bilevel patients, about your sleep quality, then it will periodically check in with other questions throughout your first month of therapy. With your permission, your responses can be shared with your care team to better help them support your therapy journey. It's all part of how we want to support you getting restful sleep to wake up with increased energy and focus.





Personal Therapy Assistant

Through myAir you have access to features like Personal Therapy Assistant for interactive, voice-guided instructions and videos to help you follow along with the device and mask setup. It also provides you with tips to adjust your mask if a leak is detected.

Image is of actual product with fictional user

The majority of surveyed patients who use Personal Therapy Assistant with their AirSense 11, part of the Air11 platform, reported that the feature helped them get started on PAP therapy.⁶

ResMed: Working for you

Your AirCurve 11 device is part of the greater family of ResMed Air Solutions. This integrated sleep therapy system of PAP devices, masks and digital health offerings is engineered to work together so you experience the benefits of therapy as soon as possible. It is also designed to allow your care team to coordinate more easily. This coordination can help them make informed decisions and support the best possible therapy and health outcomes for you.

Congratulations—you're on your way to a therapy experience designed to maximize comfort and sleep quality.





Support your start to therapy by downloading the myAir app

Or contact your equipment provider to learn more about AirCurve 11.

- * ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF < 45%) and moderate to severe predominant central sleep apnea.
- † The myAir by ResMed app is available in English and Spanish in the US. The myAir for Canada by ResMed app is available in English and French in Canada.
- ‡ Some features of myAir are only available in the myAir app and with Air11 devices.
- ** Coaching entails personalized feedback to encourage continuation of therapy. This is not a healthcare service and is not performed by licensed healthcare providers. Patients are encouraged to speak with their treating clinicians for any clinical symptoms or medical conditions.
- †† Patient consent required for Care Check-In.

1 Correa D et al . Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015;120(6):1273-85. 2 ResMed market research survey results of US AirSense 11 PAP device users. Survey conducted July 2021. n=119.

3 Javaheri S, Badr MS. Central sleep apnea: pathophysiologic classification. Sleep. 2023;46(3):zsac113. 4 Aurora RN, et al. The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses. SLEEP 2012;35(1):17-40. 5 Badr MS. Central sleep apnea: Risk factors, clinical presentation, and diagnosis, In: Chervin RD, Eichler AF editors. UpToDate. Waltham, MA: Wolters Kluwer N.V.; 2023. 6 ResMed market research survey results of US AirSense 11 PAP device users. AirSense 11 is part of the Air11 platform. Survey conducted July 2021. n=78.
7 Malhotra et al. "Patient engagement using new technology to improve adherence to positive airway pressure therapy: A retrospective analysis," CHEST. 2018: 153(4):843-850.

Distributed by ResMed Corp, 9001 Spectrum Center Boulevard, San Diego, CA 92123 USA (858) 836-5000 or (800) 424-0737 (toll-free). See ResMed.com for other ResMed locations worldwide. AirCurve 11, AirCurve 11 VAuto and AirCurve 11 ASV are trademarks and/or registered trademarks of the ResMed family of companies. Specifications may change without notice. For patent and other intellectual property information, see ResMed.com/jp. © 2024 ResMed. 10113731/1 2024-01.



